Assesment of BCR-ABL1 transcript levels at 3 months is the major determinant for outcome in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors (CROSBI ID 645589)
Prilog sa skupa u časopisu | sažetak izlaganja sa skupa | međunarodna recenzija
Podaci o odgovornosti
Katalinic, Darko
engleski
Assesment of BCR-ABL1 transcript levels at 3 months is the major determinant for outcome in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors
Assesment of BCR-ABL1 transcript levels at 3 months is the major determinant for outcome in patients with chronic myelod leukemia treated with tyrpsine kinase inhibitors
BCR-ABL1, chronic myeloid leukemia
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o prilogu
772-772.
2017.
nije evidentirano
objavljeno
10.1016/S0959-8049(17)30412-4
Podaci o matičnoj publikaciji
European journal of cancer (1990)
Amsterdam: Elsevier
0959-8049
1879-0852
Podaci o skupu
European Cancer Congress
poster
27.01.2017-30.01.2017
Amsterdam, Nizozemska
Povezanost rada
Dentalna medicina, Kliničke medicinske znanosti, Temeljne medicinske znanosti
